SGMO
Sangamo Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$105.52M
P/E Ratio
—
EPS
$-0.44
Beta
1.50
52W High
$0.84
52W Low
$0.21
50-Day MA
$0.38
200-Day MA
$0.49
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
0.40
PEG Ratio
0.00
About Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic drugs that transform the lives of patients using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company is headquartered in Brisbane, California.
Fundamentals
| Revenue (TTM) | $39.55M |
| Gross Profit (TTM) | $-73.12M |
| EBITDA | $-104.04M |
| Operating Margin | -175.50% |
| Return on Equity | -2892.00% |
| Return on Assets | -83.70% |
| Revenue/Share (TTM) | $0.14 |
| Book Value | $-0.04 |
| Price-to-Book | 18.13 |
| Price-to-Sales (TTM) | 2.67 |
| EV/Revenue | 3.066 |
| EV/EBITDA | -1.00 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 88.40% |
| Shares Outstanding | $414.27M |
| Float | $406.77M |
| % Insiders | 1.74% |
| % Institutions | 15.14% |
Analyst Ratings
Consensus ($3.75 target)
2
Buy2
HoldData last updated: 4/9/2026